New Bitai vaccine arrives in Hong Kong
The Hong Kong Special Administrative Region government announced on the 18th that the latest batch of about 860000 doses of fubitai vaccine had arrived in Hong Kong on the 18th. This batch of vaccine was produced by Fosun Pharmaceutical Co., Ltd. and biontech, and packaged in Baxter factory in Germany. It is reported that after the arrival of Bitai vaccine, the staff will check and verify the vaccine according to the established procedures to ensure that the vaccine meets the product specifications and relevant cold chain transportation standards. The government of the Hong Kong Special Administrative Region (HKSAR) said that the vaccines would be stored in standard ultra-low temperature refrigerators and kept at the temperature specified by the pharmaceutical factory.
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 18, 2022 06:30 PM
Healthcare, Financials
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
Briefing Feb 17, 2022 10:08 AM
Yingsi intelligence and Fosun Pharmaceutical reached the first milestone of strategic cooperation: nomination and targeting cd47-sirp α Small molecule compounds of signal pathway
Briefing Jan 24, 2022 02:39 PM
The main force continued to increase its position in lithium battery stocks in the late trading, and sold off banks and pharmaceutical stocks
See more
Read next
Insight
In-depth
Insight
In-depth